0001354457-23-000760.txt : 20231012
0001354457-23-000760.hdr.sgml : 20231012
20231012081848
ACCESSION NUMBER: 0001354457-23-000760
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20231012
DATE AS OF CHANGE: 20231012
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: G Medical Innovations Holdings Ltd.
CENTRAL INDEX KEY: 0001760764
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39674
BUSINESS ADDRESS:
STREET 1: 5 OPPENHEIMER ST.
CITY: REHOVOT
STATE: L3
ZIP: 7670105
BUSINESS PHONE: 972-89584777
MAIL ADDRESS:
STREET 1: 5 OPPENHEIMER ST.
CITY: REHOVOT
STATE: L3
ZIP: 7670105
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001760764
G Medical Innovations Holdings Ltd.
001-39674
5 Oppenheimer Street
Rehovot
L3
ISRAEL
7670105
972-8-958-4778
Ordinary Shares and Warrants
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2023-10-12
EX-99.25
2
gmvddelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, October 12, 2023,
G Medical Innovations Holdings Ltd.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of G Medical Innovations Holdings Ltd.,
effective at the opening of the trading session on October 23, 2023.
Based on review of information provided by the Company, Nasdaq
Staff determined that the Company no longer qualified for listing
on the Exchange pursuant to Listing Rule 5550(b) and 5250(a)(1).
The Company was notified of the Staff determination on February 16, 2023.
On February 23, 2023, the Company exercised its right to appeal
the Staff determination to the Listing Qualifications Hearings
Panel (Panel) pursuant to Rule 5815. A Panel hearing was held on
April 13, 2023. On May 11, 2023, upon review of the information
provided by the Company, the Panel determined to grant the
Company request to remain listed in the Exchange subject to
a series of milestones. Based on the Company failure to meet the terms
of the exception, on August 22, 2023, the Panel issued a final decision
denying the Company continued listing and notified the Company that trading
in the Company securities would be suspended on August 24, 2023.
The Company did not appeal the Panel decision to the Nasdaq Listing
and Hearing Review Council (Council) and the Council did not call
the matter for review. The Staff determination to delist the Company
became final on October 6, 2023.